CTRI/2010/091/001478已完成3 期
A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with Chemotherapy induced anaemia (CIA). - Nil
Pharmacosmos AS0 个研究点目标入组 350 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Men and women, aged more than 18 years.
- •2.Subjects diagnosed with cancer (non-myeloid malignancies) receiving chemotherapy at least 1 day prior to screening and who are going to receive at least two more chemotherapy cycles.
- •3.Hb 12 g/dL (7.4 mmol/L).
- •4.TfS 50%.
- •5.Serum Ferritin 800 ng/ml.
- •6.An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- •7.Willingness to participate after informed consent (including HIPAA, if applicable).
排除标准
- •1.Anaemia caused primarily by other factors than CIA.
- •2.IV or oral iron treatment within 4 weeks prior to screening visit.
- •3.Erythrypoietin treatment within 4 weeks prior to screening visit.
- •4.Blood transfusion within 4 weeks prior to screening visit.
- •5.Imminent expectation of blood transfusion on part of treating physician.
- •6.Iron overload or disturbances in enrolment of iron (e.g. haemochromatosis and haemosiderosis).
- •7.Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulfate).
- •8.Known hypersensitivity to any excipients in the investigational drug products.
- •9.Subjects with a history of multiple allergies.
- •10.Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALAT) 3 times upper normal limit).
- •11.History of Immunocompromise and/or history of Hepatitis B and/or C.
- •12.Active acute or chronic infections (assessed by clinical judgement and if deemed necessary by investigator supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- •13.Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •14.Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- •15.Planned elective surgery during the study.
- •16.Participation in any other clinical study (except chemotherapy protocol) within 3 months prior to screening.
- •17.Known intolerance to oral iron treatment.
- •18.Untreated B12 or folate deficiency.
- •19. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
研究者
相似试验
进行中（未招募）
不适用
A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with Chemotherapy induced anaemia (CIA). - P-Monofer-CIA-01on-myeloid malignancies associated with Chemotherapy induced anaemia (CIA)MedDRA version: 12Level: LLTClassification code 10064014Term: Cancer anemiaEUCTR2009-016727-53-GBPharmacosmos A/S350
进行中（未招募）
不适用
A study to compare isomaltoside 1000 (Monofer®)(taken as injections) with iron sulfate taken as tablets in patients who have cancer and anemia caused by their treatment.Patients with non-myeloid malignancies associated with Chemotherapy Induced Anemia (CIA).MedDRA version: 14.1Level: LLTClassification code 10064014Term: Cancer anemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-016727-53-SEPharmacosmos A/S350
进行中（未招募）
1 期
A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with Chemotherapy induced anaemia (CIA). - P-Monofer-CIA-01non-myeloid malignancies associated with chemotherapy induced anaemia (CIA).MedDRA version: 12.1Level: LLTClassification code 10064014Term: Cancer anemiaEUCTR2009-016727-53-DKPharmacosmos A/S350
进行中（未招募）
1 期
A study to compare isomaltoside 1000 (Monofer®)(taken as injections) with iron sulfate taken as tablets in patients who have cancer and anemia caused by their treatment.EUCTR2009-016727-53-ESPharmacosmos A/S350
进行中（未招募）
不适用
A study to compare isomaltoside 1000 (Monofer®)(taken as injections) with iron sulfate taken as tablets in patients who have cancer and anemia caused by their treatment.Patients with non-myeloid malignancies associated with Chemotherapy Induced Anemia (CIA).MedDRA version: 15.1Level: LLTClassification code 10064014Term: Cancer anemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 15.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-016727-53-DEPharmacosmos A/S350